Praxis precision medicines to host hybrid r&d day on monday, october 2, 2023

Boston, sept. 27, 2023 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will host a r&d day on monday, october 2, at 9:00 a.m. edt, virtually and in person in new york city.
PRAX Ratings Summary
PRAX Quant Ranking